SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)		3 Months Ended
	Mar. 16, 2026 USD ($)	Mar. 31, 2026 USD ($) segment	Mar. 31, 2025 USD ($)	Dec. 31, 2025 USD ($)	Jul. 03, 2025 shares
Concentration Risk [Line Items]
Private Placement issuance costs in accounts payable and accruals		$ 380,000	$ 0
Reverse stock split		1-for-3.33
Net foreign exchange gains (losses)		$ 7,000	(6,000)
Number of operating segments | segment		1
Number of reportable segments | segment		1
Contract assets		$ 0		$ 0
Costs of revenue		1,463,000	1,289,000
Advertising costs		0	0
Research and development		4,435,000	3,107,000
Impairment of long-lived assets		0	0
IPO
Concentration Risk [Line Items]
Warrants issued (in shares) | shares					168,898
Private Placement
Concentration Risk [Line Items]
Private Placement issuance costs in accounts payable and accruals	$ 380,000
Shipping and handling
Concentration Risk [Line Items]
Costs of revenue		35,000	17,000
Healthcare clinical trial activities
Concentration Risk [Line Items]
Research and development		$ 1,634,000	$ 697,000